biologic

PRIORIX

Measles, Mumps and Rubella Vaccine Live

Loss of exclusivityJune 2034projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand namePRIORIX
Active ingredientMeasles, Mumps and Rubella Vaccine Live
Strength3.4, 4.2 and 3.3LOG10
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2022
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

PRIORIX patent cliff — loss of exclusivity June 2034 | CliffBio